Acute Agitation and Aggression Treatment Market to Exceed USD 8.2 Billion by 2034, Driven by Advancements in Rapid-Acting Therapies - Latest Report by Transparency Market Research Inc.
GlobeNewswire·2025-02-06 12:50
Acute Agitation and Aggression Treatment Market is set for significant growth from 2024 to 2034, driven by the rising prevalence of psychiatric disorders and advancements in treatment approaches. Key therapies include First-Generation Anti-Psychotics (Chlorpromazine, Haloperidol), Second-Generation Anti-Psychotics (Quetiapine, Olanzapine, Ziprasidone), Benzodiazepines (Lorazepam, Midazolam), Alpha-2 Adrenergic Agonists (Clonidine, Dexmedetomidine), and Others (Droperidol, etc.). Increasing adoption of fast- ...